STOCK TITAN
  1. Home
  2. News
  3. PAVM

PAVmed Inc. - PAVM STOCK NEWS

Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.

PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.

PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.

Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.

Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.

PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.

News

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

Rhea-AI Summary
PAVmed Inc. to host a business update conference call and webcast to discuss operations, growth strategy, and financial results for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.6%
Tags
none
-
News

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.13%
Tags
none
-
News

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.82%
Tags
none
News

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

Rhea-AI Summary
Lucid Diagnostics Inc. highlights EsoCheck's advanced cell collection technology during testimony before the U.S. House of Representatives' Committee on Small Business. EsoCheck's innovative Collect & Protect® technology offers precise, noninvasive esophageal cell collection, leading to unprecedented early precancer detection results. The device's efficiency allows for high-volume testing events, with excellent patient satisfaction and DNA yields. In contrast, older 'sponge-on-a-string' technologies lack EsoCheck's precision and protection features, resulting in poor sensitivity and mechanical failures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
News

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

Rhea-AI Summary
Lucid Diagnostics Inc. announces a contract with the World Trade Center Health Program to provide EsoGuard Esophageal DNA test as a covered benefit to more than 120,000 responders and survivors of the 9/11 terrorist attacks. The test is reimbursable at $2,475.81 per test prescribed by clinicians at WTCHP's Clinical Centers of Excellence. This initiative aims to expand patient access to EsoGuard testing and prevent esophageal cancer and cancer deaths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
News

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced the publication of three clinical utility studies demonstrating the real-world clinical utility of Lucid's EsoGuard Esophageal DNA test to detect esophageal precancer. The studies document near-perfect concordance between EsoGuard results and the prescribing physician's decision whether to refer patients for upper endoscopy, with 100 percent of EsoGuard-positive patients being referred for confirmatory upper endoscopy. These results eliminate the need for hundreds of costly, invasive, and inconvenient endoscopies, demonstrating that EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.84%
Tags
none
News

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders

Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces the distribution of approximately 3.3 million shares of Lucid common stock to its shareholders as of January 15, 2024. Each PAVmed shareholder will receive a stock dividend of approximately 41 shares of Lucid common stock for every 100 shares of PAVmed common stock they own as of the record date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
dividends
-
News

PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split

Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces a dividend of approximately 3.3 million shares of Lucid Diagnostics Inc. (Nasdaq: LUCD) common stock and a 1-for-15 reverse stock split to be effective as of market open on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.35%
Tags
dividends
-
News

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) strengthens its executive team with two industry veterans, Natalie S. Carfora and James M. Fricchione, joining as Vice President, Market Access, and Vice President, Employer Markets, respectively. Shaun M. O'Neil is promoted to President and COO. These appointments aim to drive EsoGuard® payor coverage and secure direct contracts with employers and self-insured entities, crucial for translating test volume growth into revenue. Natalie Carfora brings over a decade of experience in market access and sales, while Jim Fricchione has over two decades of national health benefits experience. Shaun O'Neil, an industry veteran, has been instrumental in designing and building Lucid's commercial infrastructure and overseeing its commercial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

PAVmed Provides Business Update and Third Quarter Financial Results

Rhea-AI Summary
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) reported a 392% sequential increase in Lucid's quarterly revenue, with Veris Health's expansion efforts underway. The quarterly financial results were presented, and a webcast is scheduled for tomorrow at 8:30 AM EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings

FAQ

What is the current stock price of PAVmed (PAVM)?

The current stock price of PAVmed (PAVM) is $0.6561 as of December 24, 2024.

What is the market cap of PAVmed (PAVM)?

The market cap of PAVmed (PAVM) is approximately 7.3M.

What does PAVmed Inc. do?

PAVmed Inc. is a medical technology company that develops and commercializes innovative medical devices, diagnostics, and digital health solutions.

What are PAVmed's main products?

PAVmed's main products include the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, designed for early detection of esophageal precancer.

What is EsoGuard?

EsoGuard is a DNA test performed on esophageal cells collected noninvasively with EsoCheck, used for early detection of esophageal precancer.

Who leads PAVmed Inc.?

PAVmed Inc. is led by three experienced medical device entrepreneurs focused on rapid commercialization of medical technologies.

What recent achievements has PAVmed made?

Recent achievements include a partnership with ECAN for Esophageal Cancer Awareness Month and a successful clinical validation study for EsoGuard.

What is Veris Health?

Veris Health, a subsidiary of PAVmed, focuses on personalized cancer care through remote patient monitoring and is developing an implantable physiological monitor.

How does PAVmed enhance value creation?

PAVmed enhances value creation by employing a business model focused on capital and time efficiency, quickly bringing innovative products to market.

What areas does PAVmed operate in?

PAVmed operates in diagnostics, medical devices, and digital health sectors within the medical technology industry.

How can I access PAVmed's latest updates?

You can access the latest updates on PAVmed's operations and financial performance through their business update conference calls and webcasts.

Where can I find more information about PAVmed?

For more information, please visit PAVmed's official website at www.pavmed.com.

Stock PAVM logo
PAVmed Inc.

Nasdaq:PAVM

PAVM Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PAVM Stock Data

7.26M
9.73M
10.39%
14.6%
2.82%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK